Chordoma Combined with Trousseau Syndrome: a Case Report and Literature Review

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2024 Oct 24

PMID 39444889

Authors

Ruiying Rao

Ping Lin

Jinhe Xu

Chenxi Wang

Ying Chen

Shinji Ito

Tatsuro Mutoh

Zongyang Yu

Affiliations

Soon will be listed here.

Abstract

Background: Trousseau syndrome (TS) refers to spontaneous, recurrent, and wandering arterial and venous thromboembolic events in patients with tumors. It results from abnormalities in coagulation and fibrinolytic mechanisms of varying degrees throughout the course of the disease. It has a high fatality rate, and it is commonly seen in patients with highly invasive tumors, such as lung, pancreatic, gastrointestinal, and breast cancers; however, to date, there has been no report of TS combined with chordoma.

Case Description: A 56-year-old male with a diagnosis of chordoma underwent surgery, immunotherapy, immunotherapy combined with antiangiogenic therapy, chemotherapy combined with immunotherapy, and proton therapy for localized metastases. Subsequent to the worsening of chest tightness, a repeat chest computed tomography angiography (CTA) scan suggested pulmonary artery embolisms; eventually, a diagnosis of TS was made. After anticoagulation and synchronized antitumor therapy, the patient's condition remained recurrent, eventually leading to death.

Conclusions: TS is a frequent but easily overlooked clinical complication that can occur in a variety of tumors, including chordoma, and is currently diagnosed clinically. Thus, further exploration of its sensitive markers is needed. We have reported a case of chordoma combined with TS and conducted a literature review on TS to increase clinicians' awareness of tumor-related thromboembolism and explore strategies to optimize the diagnosis, treatment, and prevention of TS.

References

Kim S, Hong J, Kim H, Lee J, Chung P, Park K . Ischemic stroke in cancer patients with and without conventional mechanisms: a multicenter study in Korea. Stroke. 2010; 41(4):798-801. DOI: 10.1161/STROKEAHA.109.571356. View

Hasegawa Y, Setoguchi T, Sakaida T, Iuchi T . Utility of a scoring system for differentiating cancer-associated stroke from cryptogenic stroke in patients with cancer. Neurol Sci. 2020; 41(5):1245-1250. DOI: 10.1007/s10072-019-04231-5. View

Luu I, Appelboom Y, Willems J, Gielen R, Lobbes M, Kulcu K . Deferring diagnostic evaluation of suspected deep vein thrombosis using direct oral anticoagulant or low-molecular-weight heparin as a single dose anticoagulant: A prospective real-world study in a regionwide care pathway. Thromb Res. 2024; 240:109059. DOI: 10.1016/j.thromres.2024.109059. View

Schrag D, Uno H, Rosovsky R, Rutherford C, Sanfilippo K, Villano J . Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial. JAMA. 2023; 329(22):1924-1933. PMC: 10265290. DOI: 10.1001/jama.2023.7843. View

Otten H, Prins M . Venous thromboembolism and occult malignancy. Thromb Res. 2001; 102(6):V187-94. DOI: 10.1016/s0049-3848(01)00235-3. View

Ikushima S, Ono R, Fukuda K, Sakayori M, Awano N, Kondo K . Trousseau's syndrome: cancer-associated thrombosis. Jpn J Clin Oncol. 2015; 46(3):204-8. DOI: 10.1093/jjco/hyv165. View

Farge D, Frere C, Connors J, Khorana A, Kakkar A, Ay C . 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022; 23(7):e334-e347. PMC: 9236567. DOI: 10.1016/S1470-2045(22)00160-7. View

El-Shami K, Griffiths E, Streiff M . Nonbacterial thrombotic endocarditis in cancer patients: pathogenesis, diagnosis, and treatment. Oncologist. 2007; 12(5):518-23. DOI: 10.1634/theoncologist.12-5-518. View

Zhang Y, Cordato D, Shen Q, Sheng A, Hung W, Chan D . Risk factor, pattern, etiology and outcome in ischemic stroke patients with cancer: a nested case-control study. Cerebrovasc Dis. 2006; 23(2-3):181-7. DOI: 10.1159/000097639. View

10.

Lee A, Levine M, Baker R, Bowden C, Kakkar A, Prins M . Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003; 349(2):146-53. DOI: 10.1056/NEJMoa025313. View

11.

Khachatryan T, Hauschild C, Hoff J, Contractor T, Khachatryan A, Tran H . Review of Direct Oral Anticoagulants and Guide for Effective Drug Utilization. Am J Cardiovasc Drugs. 2019; 19(6):525-539. DOI: 10.1007/s40256-019-00344-6. View

12.

Young A, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C . Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018; 36(20):2017-2023. DOI: 10.1200/JCO.2018.78.8034. View

13.

Akl E, Labedi N, Barba M, Terrenato I, Sperati F, Muti P . Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev. 2011; (6):CD006650. DOI: 10.1002/14651858.CD006650.pub3. View

14.

Kahale L, Matar C, Hakoum M, Tsolakian I, Yosuico V, Terrenato I . Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. Cochrane Database Syst Rev. 2021; 12:CD006649. PMC: 8653422. DOI: 10.1002/14651858.CD006649.pub8. View

15.

Khorana A, Kuderer N, Culakova E, Lyman G, Francis C . Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008; 111(10):4902-7. PMC: 2384124. DOI: 10.1182/blood-2007-10-116327. View

16.

Mackman N . Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol. 2004; 24(6):1015-22. DOI: 10.1161/01.ATV.0000130465.23430.74. View

17.

Brunetti N, Gesuete E, De Gennaro L, Correale M, Caldarola P, Gaglione A . Direct oral anti-coagulants compared with vitamin-K inhibitors and low-molecular-weight-heparin for the prevention of venous thromboembolism in patients with cancer: A meta-analysis study. Int J Cardiol. 2017; 230:214-221. DOI: 10.1016/j.ijcard.2016.12.168. View

18.

Streiff M, Holmstrom B, Angelini D, Ashrani A, Elshoury A, Fanikos J . Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021; 19(10):1181-1201. DOI: 10.6004/jnccn.2021.0047. View

19.

Mackman N . New insights into the mechanisms of venous thrombosis. J Clin Invest. 2012; 122(7):2331-6. PMC: 3386811. DOI: 10.1172/JCI60229. View

20.

Zhao B, Jia W, Yuan Y, Li Z . Clinical analysis of twenty-one cases of acute ischemic stroke related to Trousseau syndrome. Neurol Sci. 2023; 45(4):1537-1547. DOI: 10.1007/s10072-023-07180-2. View